Introduction
Sermorelin and CJC-1295 No DAC (Modified GRF 1-29) are both synthetic analogs of growth hormone-releasing hormone (GHRH) that stimulate pituitary GH secretion through the same receptor. However, they differ in sequence modifications, metabolic stability, and clinical development history. Sermorelin is the first-generation GHRH analog with FDA approval history, while CJC-1295 No DAC incorporates additional amino acid substitutions for improved DPP-IV resistance.
Mechanism of Action Comparison
Sermorelin is a 29-amino acid peptide corresponding to the first 29 residues of native human GHRH(1-44), which is the minimum fragment retaining full biological activity. It binds the GHRH receptor on pituitary somatotrophs, activates cAMP signaling, and stimulates GH synthesis and release. Sermorelin has a half-life of approximately 10-20 minutes due to rapid DPP-IV degradation[1].
CJC-1295 No DAC (Mod GRF 1-29) incorporates four amino acid substitutions (positions 2, 8, 15, and 27) that significantly improve resistance to DPP-IV enzymatic degradation while maintaining full GHRH receptor affinity. These modifications extend the half-life to approximately 30 minutes — roughly double that of sermorelin — producing more sustained GH pulses per injection.
Key Differences
| Feature | Sermorelin | CJC-1295 No DAC |
|---|---|---|
| Sequence | Native GHRH(1-29) | Modified GRF(1-29), 4 substitutions |
| Half-life | ~10-20 minutes | ~30 minutes |
| DPP-IV Resistance | Low (rapidly degraded) | High (modified residues) |
| GH Pulse Duration | Shorter, sharper | Longer, more sustained |
| FDA History | Previously approved (Geref) | Research compound |
| Clinical Data | Extensive (decades) | Moderate |
Research Applications
Sermorelin is used in pediatric GH deficiency research (historical clinical data), anti-aging protocols, and studies requiring a clinically validated GHRH analog. CJC-1295 No DAC is preferred in combination protocols with GH secretagogues like Ipamorelin, where its longer half-life provides better temporal overlap with the secretagogue pulse. Both are used in body composition, sleep quality, and GH-axis physiology research.
Which to Choose for Your Research?
For studies requiring clinical precedent and regulatory context, sermorelin's FDA history provides a stronger foundation. For optimized pharmacokinetic performance, particularly in combination protocols with GHS peptides, CJC-1295 No DAC's improved DPP-IV resistance makes it the preferred modern GHRH analog. The CJC-1295 No DAC + Ipamorelin combination has become the most widely used GH peptide pairing in research settings.
